Riociguat oral tablet (DrugBank: Riociguat)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
88 | Chronic thromboembolic pulmonary hypertension | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04600492 (ClinicalTrials.gov) | October 16, 2020 | 19/10/2020 | THERAPY-HYBRID-BPA Trial | The Effect of Riociguat for Peak Cardiac Index on Cardiopulmonary Exercise Test in CTEPH Patients After Normalization of Pulmonary Artery Pressure by Combination Treatment of Riociguat and Balloon Pulmonary Angioplasty | Hypertension, Pulmonary | Drug: Riociguat Oral Tablet | National Hospital Organization Okayama Medical Center | Bayer Yakuhin, Ltd. | Recruiting | 18 Years | 85 Years | All | 72 | Phase 2 | Japan |